BioStock: Synact focuses on pushing forward rheumatoid arthritis project
SynAct Pharma is intent on making a turnaround after posting disappointing study results with lead asset resomelagon. The Swedish biotech is conducting a directed share issue of SEK 49.2 million to develop resomelagon further in rheumatoid arthritis. BioStock got in touch with Synact’s CSO Thomas Jonassen to learn more.Read the article at biostock.se: https://www.biostock.se/en/2024/04/synact-focuses-on-pushing-forward-rheumatoid-arthritis-project/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/